Principal Investigator
Gary Kleiner
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20200578
Clinical Trial Summary
A randomized trial of low versus moderate exposure busulfan for infants with severe combined immunodeficiency (SCID) receiving TCRab/CD19+ depleted transplantation: A Phase II study by the Primary Immune Deficiency Treatment Consortium (PIDTC) and Pediatric Blood and Marrow Transplant Consortium (PBMTC)
Phase
Phase II
Funding Agency/Sponsor
Intramural
Disease
Immunology/Infectious Disease
Contact Information
Study Contact
Gary Kleiner
Phone Number
+1 (305) 2434863
Email
gary.kleiner@miami.edu